609 related articles for article (PubMed ID: 8592483)
1. Influence of metabolic acidosis on serum 1,25(OH)2D3 levels in chronic renal failure.
Lu KC; Lin SH; Yu FC; Chyr SH; Shieh SD
Miner Electrolyte Metab; 1995; 21(6):398-402. PubMed ID: 8592483
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Rapid correction of metabolic acidosis in chronic renal failure: effect on parathyroid hormone activity.
Lu KC; Shieh SD; Li BL; Chu P; Jan SY; Lin YF
Nephron; 1994; 67(4):419-24. PubMed ID: 7969674
[TBL] [Abstract][Full Text] [Related]
4. Influence of rapid correction of metabolic acidosis on serum osteocalcin level in chronic renal failure.
Lin YF; Shieh SD; Diang LK; Lin SH; Chyr SH; Li BL; Lu KC
ASAIO J; 1994; 40(3):M440-4. PubMed ID: 8555554
[TBL] [Abstract][Full Text] [Related]
5. Acute correction of metabolic acidosis increases serum procollagen type I carboxyterminal propeptide in patients with chronic renal failure.
Chu P; Lu KC; Lin YF
J Formos Med Assoc; 2001 Nov; 100(11):748-52. PubMed ID: 11802533
[TBL] [Abstract][Full Text] [Related]
6. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.
Zisman AL; Hristova M; Ho LT; Sprague SM
Am J Nephrol; 2007; 27(1):36-43. PubMed ID: 17215573
[TBL] [Abstract][Full Text] [Related]
7. Chronic metabolic acidosis increases the serum concentration of 1,25-dihydroxyvitamin D in humans by stimulating its production rate. Critical role of acidosis-induced renal hypophosphatemia.
Krapf R; Vetsch R; Vetsch W; Hulter HN
J Clin Invest; 1992 Dec; 90(6):2456-63. PubMed ID: 1469097
[TBL] [Abstract][Full Text] [Related]
8. [Review of the concept of vitamin D "sufficiency and insufficiency"].
Gómez Alonso C; Naves Díaz M; Rodríguez García M; Fernández Martín JL; Cannata Andía JB
Nefrologia; 2003; 23 Suppl 2():73-7. PubMed ID: 12778859
[TBL] [Abstract][Full Text] [Related]
9. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure.
Pitts TO; Piraino BH; Mitro R; Chen TC; Segre GV; Greenberg A; Puschett JB
J Clin Endocrinol Metab; 1988 Nov; 67(5):876-81. PubMed ID: 3182962
[TBL] [Abstract][Full Text] [Related]
10. The interaction of PTH and dietary phosphorus and calcium on serum calcitriol levels in the rat with experimental renal failure.
Martin-Malo A; Rodriguez M; Martinez ME; Torres A; Felsenfeld AJ
Nephrol Dial Transplant; 1996 Aug; 11(8):1553-8. PubMed ID: 8856210
[TBL] [Abstract][Full Text] [Related]
11. Correction of chronic metabolic acidosis in haemodialysed patients by acetate-free biofiltration does not influence parathyroid function.
de Précigout V; Combe C; Blanchetier V; Larroumet N; Pommereau A; Potaux L; Aparicio M
Nephrol Dial Transplant; 1995; 10(6):821-4. PubMed ID: 7566610
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of secondary hyperparathyroidisms of predialysis chronic renal failure with low doses of 1.25(OH)2D3].
Kato N; Kasai K; Kawaguchi Y; Yamamoto H; Shigematu T; Sakai O
Nihon Jinzo Gakkai Shi; 1995 Oct; 37(10):543-8. PubMed ID: 7474506
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients.
Blair D; Byham-Gray L; Lewis E; McCaffrey S
J Ren Nutr; 2008 Jul; 18(4):375-82. PubMed ID: 18558303
[TBL] [Abstract][Full Text] [Related]
14. Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combination.
Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Eade Y; Johnson JR; George CR; Collett P
Miner Electrolyte Metab; 1985; 11(6):358-68. PubMed ID: 3877862
[TBL] [Abstract][Full Text] [Related]
15. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
Lee SH; Huang TS; Hsieh SJ
Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
[TBL] [Abstract][Full Text] [Related]
16. Intradialytic changes of serum magnesium and their relation to hypotensive episodes in hemodialysis patients on different dialysates.
Elsharkawy MM; Youssef AM; Zayoon MY
Hemodial Int; 2006 Oct; 10 Suppl 2():S16-23. PubMed ID: 17022745
[TBL] [Abstract][Full Text] [Related]
17. Correction of metabolic acidosis on serum albumin and protein catabolism in hemodialysis patients.
Movilli E; Viola BF; Camerini C; Mazzola G; Cancarini GC
J Ren Nutr; 2009 Mar; 19(2):172-7. PubMed ID: 19218045
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis.
Del Valle E; Negri AL; Aguirre C; Fradinger E; Zanchetta JR
Hemodial Int; 2007 Jul; 11(3):315-21. PubMed ID: 17576296
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D3 metabolites in chronic renal failure and after renal transplantation.
Lucas PA; Woodhead JS; Brown RC
Nephrol Dial Transplant; 1988; 3(1):70-6. PubMed ID: 3132643
[TBL] [Abstract][Full Text] [Related]
20. Sevelamer worsens metabolic acidosis in hemodialysis patients.
De Santo NG; Frangiosa A; Anastasio P; Marino A; Correale G; Perna A; Di Stazio E; Stellato D; Santoro D; Di Meglio E; Iacono G; Ciacci C; Savica V; Cirillo M
J Nephrol; 2006; 19 Suppl 9():S108-14. PubMed ID: 16736432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]